LmjF.36.3850, a novel hypothetical Leishmania major protein, contributes to the infection.
Animals
Antigens, Protozoan
/ genetics
Cells, Cultured
Cloning, Molecular
Cytokines
/ metabolism
Gene Expression Profiling
Humans
Leishmania major
/ pathogenicity
Leishmaniasis, Cutaneous
/ immunology
Macrophages
/ immunology
Mice
Mice, Inbred BALB C
Parasite Load
Protozoan Vaccines
/ immunology
T-Lymphocytes, Regulatory
/ immunology
Th2 Cells
/ immunology
Vaccination
Virulence
/ genetics
DNA vaccine
Leishmania
LmjF.36.3850
immunization
virulence
Journal
Immunology
ISSN: 1365-2567
Titre abrégé: Immunology
Pays: England
ID NLM: 0374672
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
09
03
2021
received:
13
01
2021
accepted:
12
03
2021
pubmed:
26
3
2021
medline:
5
10
2021
entrez:
25
3
2021
Statut:
ppublish
Résumé
Leishmania is a protozoan parasite that resides in mammalian macrophages and inflicts the disease known as leishmaniasis. Although prevalent in 88 countries, an anti-leishmanial vaccine remains elusive. While comparing the virulent and avirulent L. major transcriptomes by microarray, PCR and functional analyses for identifying a novel virulence-associated gene, we identified LmjF.36.3850, a hypothetical protein significantly less expressed in the avirulent parasite and without any known function. Motif search revealed that LmjF.36.3850 protein shared phosphorylation sites and other structural features with sucrose non-fermenting protein (Snf7) that shuttles virulence factors. LmjF.36.3850 was predicted to bind diacylglycerol (DAG) with energy value similar to PKCα and PKCβ, to which DAG is a cofactor. Indeed, 1-oleoyl-2-acetyl-sn-glycerol (OAG), a DAG analogue, enhanced the phosphorylation of PKCα and PKCβI. We cloned LmjF.36.3850 gene in a mammalian expression vector and primed susceptible BALB/c mice followed by challenge infection. We observed a higher parasite load, comparable antibody response and higher anti-inflammatory cytokines such as IL-4 and IL-10, while expression of major anti-leishmanial cytokine, IFN-γ, remained unchanged in LmjF.36.3850-vaccinated mice. CSA restimulated LN cells from vaccinated mice after challenge infection secreted comparable IL-4 and IL-10 but reduced IFN-γ, as compared to controls. These observations suggest a skewed Th2 response, diminished IFN-γ secreting Th1-T
Identifiants
pubmed: 33764520
doi: 10.1111/imm.13331
pmc: PMC8274150
doi:
Substances chimiques
Antigens, Protozoan
0
Cytokines
0
Protozoan Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
460-477Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Indian J Med Res. 2006 Mar;123(3):423-38
pubmed: 16778321
Front Immunol. 2013 Jun 19;4:156
pubmed: 23801993
Eur J Immunol. 2004 May;34(5):1433-40
pubmed: 15114677
Vet Res Forum. 2015 Winter;6(1):1-7
pubmed: 25992245
Int Immunopharmacol. 2011 Oct;11(10):1464-88
pubmed: 21616175
Vaccine. 2011 Nov 8;29(48):8783-7
pubmed: 21527301
Trends Parasitol. 2005 May;21(5):244-9
pubmed: 15837614
Clin Exp Immunol. 2014 May;176(2):283-90
pubmed: 24387292
Eur J Immunol. 1998 Dec;28(12):4213-20
pubmed: 9862358
J Exp Med. 2003 Apr 21;197(8):1037-43
pubmed: 12695487
Clin Microbiol Rev. 2001 Apr;14(2):229-43
pubmed: 11292637
Vaccine. 2009 Feb 25;27(9):1306-16
pubmed: 19162111
Sci Rep. 2014 Sep 02;4:6198
pubmed: 25178636
PLoS Pathog. 2009 Oct;5(10):e1000628
pubmed: 19834555
J Med Microbiol. 2006 Oct;55(Pt 10):1329-1331
pubmed: 17005779
Mol Biol Int. 2011;2011:343961
pubmed: 22091401
J Trop Med. 2012;2012:631460
pubmed: 21912560
Cell Rep. 2015 Nov 3;13(5):957-67
pubmed: 26565909
J Biol Chem. 2003 Mar 21;278(12):10816-23
pubmed: 12529367
Nucleic Acids Res. 2017 Jan 4;45(D1):D190-D199
pubmed: 27899635
Mol Syst Biol. 2011 Oct 11;7:539
pubmed: 21988835
Vaccine. 2014 Mar 5;32(11):1259-65
pubmed: 24462405
Biol Reprod. 2002 Jul;67(1):189-95
pubmed: 12080017
J Chem Inf Model. 2015 Nov 23;55(11):2308-14
pubmed: 26509288
Indian J Med Res. 2004 Jun;119(6):238-58
pubmed: 15243162
Nucleic Acids Res. 2015 Jan;43(Database issue):D222-6
pubmed: 25414356
Vaccine. 2016 Jun 3;34(26):2992-2995
pubmed: 26973063
Nat Protoc. 2010 Apr;5(4):725-38
pubmed: 20360767
Cell Microbiol. 1999 Jul;1(1):19-32
pubmed: 11207538
Cold Spring Harb Protoc. 2016 Feb 01;2016(2):pdb.prot083691
pubmed: 26832682
Semin Immunopathol. 2017 Apr;39(3):245-253
pubmed: 27975138
J Immunol. 2012 Mar 1;188(5):2328-37
pubmed: 22271653
Nat Med. 2004 May;10(5):540-4
pubmed: 15107845
J Infect Dis. 1999 May;179(5):1124-31
pubmed: 10191213
Nucleic Acids Res. 2013 Jan;41(Database issue):D344-7
pubmed: 23161676
Front Immunol. 2014 May 14;5:213
pubmed: 24860575
Mol Biochem Parasitol. 2010 Mar;170(1):28-36
pubmed: 20025906
Front Immunol. 2015 Oct 13;6:524
pubmed: 26528287
Vaccine. 2008 Dec 9;26(52):6759-67
pubmed: 18950671
Nucleic Acids Res. 2016 Jan 4;44(D1):D279-85
pubmed: 26673716
Trends Parasitol. 2002 Aug;18(8):332-4
pubmed: 12377273
J Exp Med. 1990 Nov 1;172(5):1359-65
pubmed: 2146362
J Microbiol Immunol Infect. 2017 Apr;50(2):160-166
pubmed: 26066544
Vaccine. 2007 Mar 30;25(14):2716-22
pubmed: 16814903
Front Immunol. 2018 May 11;9:1043
pubmed: 29868006
Vaccine. 2012 Jun 6;30(26):3834-42
pubmed: 22475861
J Immunol. 2020 May 15;204(10):2734-2753
pubmed: 32245818
Expert Rev Vaccines. 2018 Apr;17(4):323-334
pubmed: 29589966
FEBS J. 2016 Sep;283(18):3288-302
pubmed: 26910595
J Immunol. 2003 May 15;170(10):5152-8
pubmed: 12734362
Adv Appl Microbiol. 2013;82:155-84
pubmed: 23415155
Elife. 2015 Dec 15;4:
pubmed: 26670543
Nat Immunol. 2009 Mar;10(3):273-80
pubmed: 19198591